| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_29800004a1adc1fb9b840e645d147be5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6037
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate |
2021-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e6b6504f6f9fde1facd619cd9f42673
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1791ba25b1b742a7ac8da095cd78c6cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fffc9cfe362f31cf1484582e6243ea04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18f264730903247d1b79bfea31db33ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e584224ad44951c5f044468ae3507ccd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a6eb155188deaab21c402f5407d6fe2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79fcbf9e4d0a128484f551c29a8d1e6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_222b57660f6f514814c1417606d6d629
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb4a8b4b13b0d4f70e4abd8693c7d452
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9491e75e0fdcb0232cfc188c518d0ca3 |
| publicationDate |
2022-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022022756-A1 |
| titleOfInvention |
Use of epidermal growth factor depleting agents in the treatment of the chronic obstructive pulmonary disease |
| abstract |
The present invention is related to the fields of Biotechnology and Medicine. Particularly, it describes the use of epidermal growth factor (EGF) deprivation agents that contribute to lowering and/or depleting serum epidermal growth factor levels, which has implications in the treatment of the chronic obstructive pulmonary disease. These agents can be vaccine compositions comprising as active principle the conjugate between recombinant human EGF and a carrier protein. |
| priorityDate |
2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |